The Medical journal of Australia · 2006
Percutaneous radiofrequency ablation for osteoid osteoma: experience with a new treatment.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kjar Richard A, Powell Gerard J, Schilcht Stephen M, Smith Peter J, Slavin John, Choong Peter F M
Аннотация
OBJECTIVE: To review our experience with percutaneous radiofrequency ablation (RFA) for osteoid osteoma.
PARTICIPANTS, DESIGN AND SETTING: Retrospective review of 24 patients with osteoid osteoma treated with percutaneous RFA at St Vincent's Hospital, Melbourne, from August 2000 to February 2005.
MAIN OUTCOME MEASURES: Initial response to treatment, return of symptoms, time to recurrence, complications and histopathological correlation.
RESULTS: In 23 of 24 patients, there was immediate relief of symptoms. One-third of patients had a return of symptoms. The 24 patients underwent a total of 32 RFA procedures. Of the eight patients who had a recurrence, five had an initial lesion > or = 10 mm in maximum diameter. Twenty-three of the 24 patients were pain-free at the end of the study period. Patients were followed up for a median of 26 months. There were no long-term complications.
CONCLUSIONS: Percutaneous RFA is a safe and efficacious treatment for osteoid osteoma with a low morbidity rate. Despite recurrence after treatment, re-treatment is simple and effective.
PARTICIPANTS, DESIGN AND SETTING: Retrospective review of 24 patients with osteoid osteoma treated with percutaneous RFA at St Vincent's Hospital, Melbourne, from August 2000 to February 2005.
MAIN OUTCOME MEASURES: Initial response to treatment, return of symptoms, time to recurrence, complications and histopathological correlation.
RESULTS: In 23 of 24 patients, there was immediate relief of symptoms. One-third of patients had a return of symptoms. The 24 patients underwent a total of 32 RFA procedures. Of the eight patients who had a recurrence, five had an initial lesion > or = 10 mm in maximum diameter. Twenty-three of the 24 patients were pain-free at the end of the study period. Patients were followed up for a median of 26 months. There were no long-term complications.
CONCLUSIONS: Percutaneous RFA is a safe and efficacious treatment for osteoid osteoma with a low morbidity rate. Despite recurrence after treatment, re-treatment is simple and effective.